N-(isopropyl)-N'-(3,4-dichlorophenyl)-guanidine | 57004-87-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(isopropyl)-N'-(3,4-dichlorophenyl)-guanidine
• 英文别名: Guanidine, N-(3,4-dichlorophenyl)-N'-(1-methylethyl)-；1-(3,4-dichlorophenyl)-2-propan-2-ylguanidine
• CAS: 57004-87-2
• 化学式: C₁₀H₁₃Cl₂N₃
• 分子量: 246.139
• InChiKey: NOLBMHUJUOIAFK-UHFFFAOYSA-N

物化性质

• 熔点：
  179 °C
• 沸点：
  305.6±52.0 °C(Predicted)
• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  50.4
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 海关编码：
  2925290090

反应信息

• 作为反应物：
  描述：

  1-isopropyl-2-methylsulfanyl-1H-imidazole-4,5-dione 、 N-(isopropyl)-N'-(3,4-dichlorophenyl)-guanidine 以 氯仿 为溶剂， 以20%的产率得到N-(3,4-dichloro-phenyl)-N'-(1-isopropyl-4,5-dioxo-4,5-dihydro-1H-imidazol-2-yl)-N''-isopropylguanidine
  参考文献：
  名称：

  New imidazolidinedione derivatives as antimalarial agents

  摘要：

  A series of new N-alky- and N-alkoxy-imidazolidinediones was prepared and assessed for prophylactic and radical curative activities in mouse and Rhesus monkey models. New compounds are generally metabolically stable, weakly active in vitro against Plasmodium falciparum clones (D6 and W2) and in mice infected with Plasmodium berghei sporozoites. Representative compounds 8e and 9c showed good causal prophylactic activity in Rhesus monkeys dosed 30 mg/kg/day for 3 consecutive days by IM, delayed patency for 19-21 days and 54-86 days, respectively, as compared to the untreated control. By oral, 9c showed only marginal activity in causal prophylactic and radical curative tests at 50 mg/kg/day x 3 and 30 mg/kg/day x 7 plus chloroquine 10 mg/kg for 7 days, respectively. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2010.12.028
• 作为产物：
  描述：

  1-(3,4-dichlorophenyl)-2-methylisothiourea hydroiodide 、 异丙胺 在 sodium carbonate 作用下， 以 甲醇 、 水 为溶剂， 反应 18.0h， 以92%的产率得到N-(isopropyl)-N'-(3,4-dichlorophenyl)-guanidine
  参考文献：
  名称：

  New imidazolidinedione derivatives as antimalarial agents

  摘要：

  A series of new N-alky- and N-alkoxy-imidazolidinediones was prepared and assessed for prophylactic and radical curative activities in mouse and Rhesus monkey models. New compounds are generally metabolically stable, weakly active in vitro against Plasmodium falciparum clones (D6 and W2) and in mice infected with Plasmodium berghei sporozoites. Representative compounds 8e and 9c showed good causal prophylactic activity in Rhesus monkeys dosed 30 mg/kg/day for 3 consecutive days by IM, delayed patency for 19-21 days and 54-86 days, respectively, as compared to the untreated control. By oral, 9c showed only marginal activity in causal prophylactic and radical curative tests at 50 mg/kg/day x 3 and 30 mg/kg/day x 7 plus chloroquine 10 mg/kg for 7 days, respectively. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2010.12.028

文献信息

• CURABLE COMPOSITION
  申请人：Kaneka Corporation

  公开号：EP1990371A1

  公开（公告）日：2008-11-12

  The present invention has its object to provide a curable composition which comprises a reactive silyl group-containing organic polymer, does not contain, as a silanol condensation catalyst, any organotin type curing catalyst currently of concern because of the toxic feature thereof, is excellent in surface curability and depth curability and, further, can provide cured products excellent in adhesiveness; the above obj ect can be achieved by a curable composition which comprises: an organic polymer (A) containing a silicon-containing group capable of crosslinking under siloxane bond formation; and a guanidine compound (B-1), as a silanol condensation catalyst (B), represented by the general formula (1):         R1N=C(NR12)2     (1) (wherein one of the five R1s is an aryl group and the other four R1s each independently is a hydrogen atom or a hydrocarbon group in which the carbon atom at position 1 is saturated).

  本发明的目的是提供一种可固化组合物，该组合物包括含活性硅烷基团的有机聚合物，作为硅烷醇缩合催化剂，不含任何目前因其毒性特征而受到关注的有机锡类固化催化剂，具有优异的表面固化性和深度固化性，而且，可提供具有优异粘合性的固化产品；上述目的可通过一种可固化组合物来实现，该组合物包括：含硅烷基团的有机聚合物(A)；作为硅烷醇缩合催化剂(B)的胍化合物(B-1)：一种有机聚合物 (A)，其中含有能在硅氧烷键形成下交联的含硅基团；和一种胍化合物 (B-1)，作为硅醇缩合催化剂 (B)，由通式 (1) 表示： R1N=C(NR12)2 (1) (其中五个 R1s 中的一个为芳基，另外四个 R1s 分别独立地为氢原子或碳原子位于第 1 位为饱和的烃基）。
• CURABLE COMPOSITION AND CURED PRODUCT THEREOF
  申请人：Kaneka Corporation

  公开号：EP2338938A1

  公开（公告）日：2011-06-29

  The present invention aims to provide a curable composition without adverse effects on the environment, which exhibits excellent curability without containing a toxic organotin curing catalyst, and gives a cured product that does not have discoloration and cracks on the surface thereof even after being exposed to the atmosphere and ultraviolet light for a long time. The present invention also aims to provide the cured product. The curable composition comprises: (A) an organic polymer having a reactive silyl group; (B) a guanidine compound having a specific structure; and (C) a phosphorus compound that has an aryl group, has a phosphorus atom with an oxi.dation number of +5, and has a melting point of 23°C or higher.

  本发明的目的是提供一种对环境无不良影响的固化组合物，该组合物不含有毒的有机锡固化催化剂，具有优异的固化性能，即使长期暴露在大气和紫外线下，其表面也不会出现变色和裂纹。本发明还旨在提供固化产品。固化组合物包括：(A) 具有活性硅基的有机聚合物；(B) 具有特定结构的胍化合物；(C) 具有芳基、磷原子的阳离子数为 +5、熔点为 23℃或更高的磷化合物。
• US7960459B2
  申请人：——

  公开号：US7960459B2

  公开（公告）日：2011-06-14
• US8853309B2
  申请人：——

  公开号：US8853309B2

  公开（公告）日：2014-10-07
• New imidazolidinedione derivatives as antimalarial agents
  作者：Liang Zhang、Ramadas Sathunuru、ThuLan Luong、Victor Melendez、Michael P. Kozar、Ai J. Lin

  DOI：10.1016/j.bmc.2010.12.028

  日期：2011.2

  A series of new N-alky- and N-alkoxy-imidazolidinediones was prepared and assessed for prophylactic and radical curative activities in mouse and Rhesus monkey models. New compounds are generally metabolically stable, weakly active in vitro against Plasmodium falciparum clones (D6 and W2) and in mice infected with Plasmodium berghei sporozoites. Representative compounds 8e and 9c showed good causal prophylactic activity in Rhesus monkeys dosed 30 mg/kg/day for 3 consecutive days by IM, delayed patency for 19-21 days and 54-86 days, respectively, as compared to the untreated control. By oral, 9c showed only marginal activity in causal prophylactic and radical curative tests at 50 mg/kg/day x 3 and 30 mg/kg/day x 7 plus chloroquine 10 mg/kg for 7 days, respectively. Published by Elsevier Ltd.